Introduction to the PIH Animal Model

Animal models of pregnancy-induced hypertension (PIH) are essential tools for investigating the pathogenesis of hypertensive disorders of pregnancy (HDP) and preeclampsia (PE), as well as for evaluating pharmacological interventions. These models are established through mechanisms such as placental ischemia–hypoxia, manipulation of vasoactive substances, inflammatory stimulation, genetic modification, or pharmacological induction, leading to characteristic pathological features in pregnant animals, including elevated blood pressure, proteinuria, placental dysfunction, fetal growth restriction, and endothelial injury—thus closely mimicking the clinical course of pregnancy‑related hypertension. By monitoring changes in blood pressure, urinary protein levels, placental histopathology, inflammatory cytokines, and angiogenesis‑related markers, researchers can systematically assess disease mechanisms and the protective effects of candidate therapeutics on maternal and placental function, making these models widely applicable to basic research on pregnancy‑induced hypertension and preeclampsia, as well as to the development of novel therapeutics.

Service Advantages of Aniphe BioLab’s PIH Animal Model Platform

Leveraging a well-established platform for studying pregnancy-related diseases and extensive expertise in model development, Aniphe BioLab offers robust and reliable services for constructing animal models and evaluating drug efficacy in the context of gestational hypertension and preeclampsia.

	The modeling protocol is well-established. Supports multiple classic modeling methods, such as L-NAME, to meet diverse research needs.
	The model is stable and reliable. It can stably manifest typical phenotypes such as elevated blood pressure, proteinuria, and placental dysfunction.
	Comprehensive evaluation metrics It encompasses key endpoints such as blood pressure monitoring, urinary protein testing, placental pathology, and fetal development assessment.
	Mechanism research support It is possible to conduct assays to investigate related mechanisms such as angiogenesis, inflammatory responses, and oxidative stress.
	The experimental protocol is flexible. Customize a personalized research protocol based on the drug’s characteristics and the study objectives.
	Data Quality Assurance Standardized procedures and QA management throughout the entire workflow ensure that experimental data are accurate, reliable, and traceable.
	One-stop technical services We provide end-to-end support, including model development, pharmacological efficacy evaluation, sample analysis, and data interpretation.

Modeling cycle	1–2 weeks
Laboratory animals	SD rat
Positive drug	Antihypertensive agents: calcium channel blockers (nifedipine), β‑blockers (labetalol), angiotensin-converting enzyme inhibitors (lisinopril—use only postpartum; contraindicated in pregnancy), and hydralazine. Commonly used clinical drugs: methyldopa (a classic positive control) and magnesium sulfate (a positive control used for the prevention of eclampsia).
Application areas	It is primarily used for investigating the pathogenesis of gestational hypertension and preeclampsia, evaluating the efficacy and safety of novel therapeutic agents, and conducting research on placental dysfunction, maternal–fetal interface regulation, and fetal development, thereby providing critical experimental evidence for the development of disease prevention and treatment strategies.

Construction of the PIH animal model

L-NAME drinking water method: L-NAME (Nω-nitro-L-arginine methyl ester) is a non-selective nitric oxide synthase (NOS) inhibitor that, by inhibiting nitric oxide production, induces vascular dysfunction and enhanced vasoconstriction, thereby mimicking the hypertensive phenotype of pregnancy. Typically, during the mid-to-late stages of gestation in rats or mice, L-NAME is added to the drinking water at a specified concentration and administered continuously for a defined period, leading to progressive increases in blood pressure, proteinuria, placental hypoperfusion, placental tissue damage, and fetal growth restriction. This model effectively replicates the endothelial dysfunction and placental abnormalities observed in patients with preeclampsia, offering advantages such as ease of operation, high reproducibility, and a high success rate in model establishment. It is widely employed in studies of the pathogenesis of gestational hypertension and preeclampsia, as well as in the evaluation of the efficacy of relevant therapeutic agents.